Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 6/20 | 0.39 |
| ▸ | TACR1 | P25103 | 6/20 | 0.39 |
| ▸ | TAC3 | Q9UHF0 | 2/20 | 0.38 |
| ▸ | SPTLC2 | O15270 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TACR3 | P29371 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2799901 | 1.00 | TACR2 (0.39) | TACR2TACR1TAC3SPTLC2LMNA | |
| SCHEMBL7934979 | 1.00 | TACR2 (0.39) | TACR2TACR1TAC3SPTLC2LMNA | |
| SCHEMBL2797617 | 0.89 | TACR2 (0.40) | TACR2TACR1TAC3TACR3SMN1; SMN2 | |
| SCHEMBL1937147 | 0.89 | TACR2 (0.40) | TACR2TACR1TAC3TACR3SMN1; SMN2 | |
| SCHEMBL7931113 | 0.89 | TACR2 (0.40) | TACR2TACR1TAC3TACR3SMN1; SMN2 | |
| SCHEMBL7931924 | 0.89 | TACR1 (0.43) | TACR2TACR1TAC3TACR3 | |
| SCHEMBL2796395 | 0.89 | TACR1 (0.43) | TACR2TACR1TAC3TACR3 | |
| SCHEMBL1936739 | 0.89 | TACR1 (0.43) | TACR2TACR1TAC3TACR3 | |
| SCHEMBL2800563 | 0.88 | TACR2 (0.43) | TACR2TACR1TAC3TACR3 | |
| SCHEMBL7934322 | 0.88 | TACR2 (0.43) | TACR2TACR1TAC3TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293770-B2 | Pyrrolidine derivatives as NK-3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2331500-A1 | PYRROLIDINE N-BENZYL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20100168088-A1 | PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | US | disclosed |
| WO-2010040663-A1 | PYRROLIDINE N-BENZYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168088-A1 | PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | OPRK1, OPRL1, OPRD1 | TACR2 10/4885TACR1 8/4885TAC3 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.